Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient

Intervirology

Volumn 55, Issue 5, 2012, Pages 380-384

  Lee, Hyun Woong ^a   Kim, Hyung Joon ^a   Hong, Sun Pyo ^b   Cha, Bong Ki ^a   Chang, Hye Young ^a   Choi, Chang Hwan ^a   Do, Jae Hyuk ^a   Kim, Jae Gyu ^a   Chang, Sae Kyung ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b GeneMatrix Inc   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir; Nucleoside naive; Resistance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; DRUG EFFECT; GENOTYPE; HEPATITIS B; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE;

HEPATITIS B VIRUS;

EID: 84861459513     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000336561     Document Type: Article

References (14)

1. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett- Smith H: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
2. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
3. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ: Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-1665.
4. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U: Entecavir treatment for up to 5 years in patients with hepatitis B e antigen- positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
5. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
6. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
7. Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M: Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009; 3: 403-410.
8. Ghany MG, Doo EC: Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49:S174-S184.
9. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y: Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008; 6: 268-274.
10. Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP: Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441-449.
11. Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP: Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130: 1144-1152.
12. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO: Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40: 837-844.
13. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C: Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265.
14. Hulgan T, Haas DW: Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. J Infect Dis 2006; 194: 1471-1474.